Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Mortality at one year in post PCI myocardial infarction

Courtesy of Dr. Brian Nazareth Donato.

Mortality at One Year in Post PCI MI Multiple definitions with biomarkers and variable thresholds have been proposed to diagnose post procedural MI. The last update of the Third Universal Definition of Myocardial Infarction decided to use only troponin values with a threshold >5 over the normal value, on top of the clinical evidence by ECG, echocardiography or symptoms of ischemia to differentiate it from myocardial injury. After this last definition, SCAI used troponin thresholds >70 over normal values to define clnically relevant AMI type 4 a.

 

This retrospective study analyzed patients with stable and unstable angina and non ST myocardial infarction from one single institution during one year. These patients received PCI and troponin levels were analyzed before and after procedure. The study assessed mortality, recurrent AMI and repeat revascularization.  

 

Results: of 516 analyzed patients, 53 (10.3%) presented AMI type 4a, 116 (22.5%) myocardial injury (5 fold troponin elevation over normal values) and 347 (67.2%) did not show any significant changes in cardiac marker values, which made them the control group.

 

At one year follow up, there were no clinically significant differences in mortality between the three groups (p=0.13). Recurrent AMI was similar in both AMI 4a and myocardial injury groups, which showed significantly higher values than the control group (p=0.03).

 

Procedural complexity varied between the groups: there was a higher number of stents, longer stent length, more use of rotational atherectomy and more bifurcations treatments in both the AMI 4 a group and MI injury group compared to the control group. When these two were compared against each other, the need for bifurcations was higher in the AMI 4a group.

 

Conclusions

AMI type 4a was not associated with increased mortality at one year follow up, and it presented higher risk of recurrent AMI, as did MI injury. The higher number of stents, length of stents, bifurcations treatment and the use of rotational atherectomy were associated with higher AMI 4a and myocardial injury incidence.

 

Editorial Comment

There is a long history of interests and controversy around the definition of periprocedural infarction. What matters is whether it is associated with subsequent adverse outcomes, especially mortality.

 

Even though this article ─given its design and its sample size─ cannot provide categorical results, it provides encouraging information: a significant number of PCI patients (33% of the population) evolved with increased biomarkers that more often than not prolong hospitalization and even the need for new coronary angiograms justified only by troponin values that are more and more sensitive to diagnosis, and cannot be associated to mortality increase.

 

Courtesy of Dr. Brian Nazareth Donato.

Hospital Britanico de Buenos Aires, Argentina.

 

Original title: Type 4a myocardial infarction: incidence, risk factors, and long-term outcomes.

Reference  Catheterization and Cardiovascular Interventions DOI 10.1002/ccd.  Xiaoyu Yang, Hector Tamez, Carol Lai, Kalon Ho, and Donald Cutlip.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...